Nasdaq · Healthcare
Q32 Bio Inc. (QTTB)
As-reported financials and recent SEC filings for Q32 Bio Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$53.7M
Net income
$29.8M
Net margin
55.5%
Diluted EPS
$2.42
ROE
71.0%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $53.7M | $0 | $-6.7M | $3.2M | $34.0M |
| Gross profit | — | — | — | — | — |
| Operating income | $16.9M | $-66.1M | $-48.3M | $-133.3M | $-95.9M |
| Net income | $29.8M | $-47.7M | $-53.7M | $-5.0M | $-95.8M |
| Diluted EPS | $2.42 | $-6.58 | $-5.50 | $-0.53 | $-10.13 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →S-32026-06-25
View on EDGAR →42026-06-16
View on EDGAR →42026-06-16
View on EDGAR →42026-06-16
View on EDGAR →42026-06-16
View on EDGAR →42026-06-16
View on EDGAR →42026-06-16
View on EDGAR →Largest Healthcare peers
Go deeper on QTTB
Search Q32 Bio Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.